F. Goldstein
9 Papers
94 Citations
F. Goldstein is an academic researcher. The author has contributed to research in topics: Minimum inhibitory concentration & Plasmid. The author has an hindex of 8, co-authored 9 publications.
Chat about Author
Papers
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing
Gunnar Kahlmeter,Dfj Brown,F. Goldstein,Alasdair P. MacGowan,Johan W. Mouton,Inga Odenholt,Arne C. Rodloff,C.-J. Soussy,Martin Steinbakk,F Soriano,O Stetsiouk +10 more
TL;DR: Starting with the current issue, a series of EUCAST Technical Notes will be published in CMI, based on the rationale documents produced by EUCAST for each of the antimicrobial agents studied, with the aim of highlighting important background information underlying decisions on breakpoints made by EUCast.
540
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Gunnar Kahlmeter,Derek J. Brown,F. Goldstein,Alasdair P. MacGowan,Johan W. Mouton,Anders Österlund,Arne C. Rodloff,Martin Steinbakk,Pavla Urbaskova,Alkiviadis Vatopoulos +9 more
TL;DR: This document is intended to be used for educational purposes only and should not be relied on as a guide for making decisions about major decisions about torrential downpours.
OXA-35 is an OXA-10-related β-lactamase from Pseudomonas aeruginosa
TL;DR: Pseudomonas aeruginosa clinical isolate PA35 is resistant to amino- and ureido-penicillins, has intermediate susceptibility to cefsulodin, cefepime and aztreonam, and is susceptible to imipenem and ceftazidime, and a new beta-lactamase variant, OXA-35, is revealed.
38
False synergy between vancomycin and β-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods
TL;DR: The combination of vancomycin and beta-lactams is often considered synergistic and has been recommended for the treatment of glycopeptide-intermediate Staphylococcus aureus infections, but a synergistic effect was observed for teicoplanin under the same conditions.
21
•Journal Article
[Treatment of severe botulism with 3,4-diaminopyridine]].
M Dock,A. Ben Ali,A Karras,Benoit Misset,Maité Garrouste-Orgeas,E Deletie,F. Goldstein,Jean Carlet +7 more
TL;DR: A case of nutritional toxin B botulism successfully treated with 3,4-diaminopyridine, the efficacy of which had been suggested by the review of experimental literature, led to rapid and clear improvement, probably due to its potentiating effect on acetylcholine release in the neuromuscular junction.
19